Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by 90yhll2

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (2)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05869279Phase 1/2RecruitingPrimary

Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

NCT00421395Phase 1/2Completed

Safety Study of NHL With 90Y-hLL2 IgG

Showing all 2 trials

Research Network

Common Treatments

  • 90yhll21
  • Carcikcd191

Active Sponsors

  • Gilead Sciences1
  • Fondazione Matilde Tettamanti Menotti De Marchi Onlus1
  • Fondazione Tettamanti1

Top Investigators

Related Conditions

  • Bnon Hodgkin Lymphoma And Chronic Lymphocytic Leukemia1
  • Cll1
  • Nhl1
  • Nonhodgkins Lymphoma1

Activity Timeline